Comparative Efficacy and Safety of Fexuprazan Versus Esomeprazole for GERD

A meta-analysis of five clinical studies comparing the potassium-competitive acid blocker fexuprazan to the proton-pump inhibitor esomeprazole for treating gastroesophageal reflux disease. The dataset includes results from 965 patients over a mean treatment period of 9.6 weeks, compiled by Omar Abureesh and published on figshare in 2026. It reports efficacy outcomes, adverse events, and statistical measures like standardized mean differences and risk ratios.

Use Cases

• Conducting a comparative meta-analysis based on GERD symptom scores and patient-reported symptom improvement.
• Assessing drug safety profiles based on the incidence of treatment-emergent adverse events (TEAEs) and adverse drug reactions (ADRs).
• Evaluating statistical heterogeneity in clinical trial results based on reported I² values and p-values.
• Comparing the efficacy of potassium-competitive acid blockers (P-CABs) versus proton-pump inhibitors (PPIs) for GERD.

Strengths

• Includes data from 965 patients across five studies, providing a consolidated view.
• Reports specific statistical results, including standardized mean differences (SMD -0.41) and risk ratios (RR 0.85, 1.07).
• Uses a systematic review methodology with Cochrane's risk of bias assessment tool.
• Has a clear license (CC-BY-4.0) for open reuse.

Limitations

• The dataset is very small (17.7 KB), indicating limited scope and likely summary-level data only.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale analysis.

Provenance

Source

Omar Abureesh via figshare.

Collection Method

Systematic review and meta-analysis of published clinical trials.

Freshness

Last updated 2026-05-07 05:42:16; freshness should be verified.